Rezolute(RZLT) - 2026 Q2 - Quarterly Results

Financial Performance - As of December 31, 2025, cash, cash equivalents, and investments in marketable securities totaled $132.9 million, down from $167.9 million as of June 30, 2025[5]. - The net loss for Q2 fiscal 2026 was $22.8 million, compared to a net loss of $15.7 million for the same period in the previous year[7]. - The accumulated deficit as of December 31, 2025, was $444.8 million, compared to $403.9 million as of June 30, 2025[13]. Expenses - Research and development (R&D) expenses for Q2 fiscal 2026 were $14.3 million, an increase from $12.6 million in the same period last year, primarily due to higher clinical trial activities and employee-related expenses[6]. - General and administrative (G&A) expenses rose to $9.9 million in Q2 fiscal 2026, compared to $4.5 million in the prior year, driven by increased professional fees and severance benefits[7]. - The total operating expenses for Q2 fiscal 2026 were $24.2 million, up from $17.1 million in Q2 fiscal 2025[13]. Clinical Trials and Studies - In the sunRIZE Phase 3 study, reductions in hypoglycemia events were observed, but were not statistically significant compared to placebo[4]. - 75% of patients in the Expanded Access Program (EAP) achieved complete discontinuation of IV dextrose/total parenteral nutrition (TPN), supporting the efficacy of ersodetug[4]. - The company plans to meet with the FDA under Breakthrough Therapy Designation to discuss next steps for the ersodetug program[4]. - Enrollment for the upLIFT Phase 3 study is ongoing, with topline results expected in the second half of 2026[4].